US-based Symbiomix is focused on bringing innovative therapies to the market for gynaecologic infections. Photo: BloombergMumbai: Lupin Ltd on Wednesday said its US subsidiary has acquired Symbiomix Therapeutics LLC for a cash consideration of $150 million in a bid to expand its presence in women’s health segment. US-based Symbiomix is focused on bringing innovative therapies to the market for gynaecologic infections that can have serious health consequences. In September this year, the US Food and Drug Administration (FDA) approved Symbiomix’s lead product, Solosec oral granules, for the treatment of bacterial vaginosis in adult women. The acquisition of Symbiomix and its brand Solosec significantly expands Lupin’s branded women’s health specialty business, which is at present anchored by Methergine tablets, the company said.

Source: Mint October 11, 2017 06:33 UTC